Emergent BioSolutions Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Emergent BioSolutions (EBS) Misses Q1 EPS by 25c
May 3, 2018 4:41 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.03), $0.25 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $117.8 million versus the consensus estimate of $140.42 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More